Typhoid Fever
Conditions
Keywords
Salmonella Typhi, Salmonella Paratyphi A, Typhoid fever, Paratyphoid fever, Enteric fever, Conjugate vaccine, First-time-in-human
Brief summary
A bivalent Typhoid and Paratyphoid A conjugate investigational vaccine aimed to prevent both typhoid and paratyphoid enteric fever in infants and older age groups has been developed by GlaxoSmithKline (GSK). The purpose of this first-time-in-human study is to evaluate the safety and immunogenicity profile of a low and a full dose of the investigational vaccine, formulated with or without adjuvant, administered in 2 doses, 24 weeks apart, in healthy adults 18 to 50 years of age in Europe.
Interventions
1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.
BIOLOGICALTYP04A Low Dose without Alum investigational vaccine
2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
BIOLOGICALTYP04B Full Dose without Alum investigational vaccine
2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
BIOLOGICALTYP03A Low Dose with Alum investigational vaccine
2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
BIOLOGICALTYP03B Full Dose with Alum investigational vaccine
2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
BIOLOGICALGSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.
Sponsors
Biological E. Limited
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Data will be collected in an observer-blind (Day 1 to Day 29) and in a Single-blind (Day 29 to Day 337) manner with participants and investigator blinded.
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants who, in the opinion of the Investigator, can and will comply with the requirements of the Protocol (e.g., completion of the diary cards, return for follow-up visits). * Written informed consent obtained from the participant prior to performance of any study specific procedure. * Healthy participants as established by medical history, clinical examination, and screening laboratory investigations. * Participant satisfying screening requirements. * Participant seronegative for human immunodeficiency virus, hepatitis B, and hepatitis C at Screening. * A male or female participant between, and including, 18 and 50 years of age at the time of the first study intervention administration. * Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. * Female participants of childbearing potential may be enrolled in the study if the participant: * has practiced adequate contraception for 1 month prior to study intervention administration, and * has a negative pregnancy test on the day of study intervention administration, and * has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
Exclusion criteria
Medical conditions * Progressive, unstable or uncontrolled clinical conditions. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. * Hypersensitivity, including allergy, to medicinal products or medical equipment whose use is foreseen in this study. * Clinical conditions representing a contraindication to intramuscular vaccination and blood draws. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). * Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study. * Acute\* or chronic illness, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests. \*Participants with a minor illness (such as mild diarrhoea or mild upper respiratory infection) without fever may be enrolled at the discretion of the Investigator. * Any clinically significant\* haematological and/or biochemical laboratory abnormality. \*The Investigator should use his/her clinical judgement to decide which abnormalities are clinically significant. * Confirmed positive COVID-19 test during the period starting 14 days before the first administration of study vaccines (Day -14 to Day 1). * Any other clinical condition that, in the opinion of the Investigator, might pose additional risk to the participant due to participation in the study. * Confirmed or suspected autoimmune diseases (e.g., vitiligo, autoimmune thyroiditis). Prior/Concomitant therapy * Previous administration of any type of Typhoid vaccine (Ty21a, Vi-PS, or Typhoid conjugate vaccine). * Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study interventions during the period starting 30 days before the first administration of study vaccines (Day -30 to Day 1), or planned use during the study period. * A vaccine not foreseen by the study protocol administered during the period starting at -14 days before the first dose (-21 days in the case of live vaccines) and ending 28 days after the last dose of study intervention administration\*, with the exception of flu and COVID-19 vaccines, administered during the period starting at 7 days before and 7 days after each dose (14 days before and 14 days after in case of live vaccines). \*In case emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organised by public health authorities outside the routine immunisation programme, the time period described above can be reduced if, necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly. When regulations allow, the recommended time intervals for administration of these vaccines are at least 7 days before or 7 days after (at least 14 days before or 14 days after in case of live vaccines) each dose of study intervention administration. * Administration of long-acting immune-modifying drugs at any time during the study period (e.g., infliximab). * Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention or planned administration during the study period. * Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose. For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants. Inhaled and topical steroids are allowed. Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug/invasive medical device). Other exclusions * History of travel to countries of Asia that are considered endemic\* for enteric fever in the last 3 years. \*this also includes travel during study duration. * Pregnant or lactating female. * Female participants planning to become pregnant or planning to discontinue contraceptive precautions. * History of or current chronic alcohol consumption and/or drug abuse. * Any study personnel or immediate dependents, family, or household member.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | At Day 176 compared to Day 169 (Baseline) | Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, hematocrit, lymphocytes, monocytes, neutrophils, platelets, leukocytes. Hepatic laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and renal laboratory parameters include creatinine and blood urea. Categories reported when comparing Day 169 (baseline) and Day 176 hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Range level being classified as below, within or above the normal range. |
| Number of Participants With Solicited Administration-site Events After the Second Vaccination | From Day 169 to Day 175 | Solicited administration site events included pain, redness, and swelling. |
| Number of Participants With Solicited Systemic Events After the First Vaccination | From Day 1 to Day 7 | The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), fever, headache, and myalgia (muscle pain). Fever is defined as body temperature more than or equal to (\>=) 38.0 degrees Celsius (°C). |
| Number of Participants With Solicited Systemic Events After the Second Vaccination | From Day 169 to Day 175 | The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), fever, headache, and myalgia (muscle pain). |
| Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination | From Day 1 to Day 28 | An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. |
| Number of Participants With Unsolicited Adverse Events After the Second Vaccination | From Day 169 to Day 196 | An unsolicited adverse event is defined as an adverse event that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. |
| Number of Participants With Any Serious Adverse Events (SAEs) | From Day 1 to Day 197 | An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. |
| Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | From Day 1 to Day 197 | Any AEs including SAEs that lead to withdrawal from the study are considered under this outcome measure. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact. |
| Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration | From Day 1 to Day 197 | An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. SAEs that lead to withholding of the study intervention administration were considered under this outcome measure. |
| Number of Participants With AEs Leading to Withholding Further Study Intervention Administration | From Day 1 to Day 197 | An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. AEs that lead to withholding of the study intervention administration were considered under this outcome measure. |
| Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | At Day 8 compared to Day 1 (Baseline) | Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, hematocrit, lymphocytes, monocytes, neutrophils, platelets, leukocytes. Hepatic laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and renal laboratory parameters include creatinine and blood urea. Categories reported when comparing Day 1 (baseline) and Day 8 hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Range level being classified as below, within or above the normal range. |
| Number of Participants With Solicited Administration-site Events After the First Vaccination | From Day 1 to Day 7 | Solicited administration site events included pain, redness, and swelling. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | From Day 197 to Day 337 | Any AEs including SAEs that lead to withdrawal from the study are considered under this outcome measure. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact. |
| Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | At Day 1 (pre-dose 1), Day 29, Day 169 (pre-Dose 2), Day 176 and Day 197 | Anti-Vi specific IgG antibodies were measured by an anti-Vi IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit. Blood samples were collected at specified timepoints. |
| Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | At Day 29, Day 169, Day 176, and Day 197 compared to Day 1 (baseline) | Anti-Vi specific IgG antibodies were measured by an anti-Vi IgG ELISA kit. Blood samples were collected at specified timepoints. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint. |
| GMR for Anti-Vi Antigen IgG Antibody Concentrations | At Day 176 and Day 197 compared to Day 169 (baseline) | Anti-Vi specific IgG antibodies were measured by an anti-Vi IgG ELISA kit. Blood samples were collected at specified timepoints. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint. |
| GMC of Anti-O:2 IgG Antibody Concentrations | At Day 1 (pre-dose 1), Day 29, Day 169 (pre-dose 2), Day 176 and Day 197 | Anti-O:2 IgG antibodies in serum were measured by an ELISA assay. Blood samples were collected at specified timepoints. |
| GMR for Anti-O:2 IgG Antibody Concentrations | At Day 29, Day 169, Day 176, and Day 197 compared to Day 1 (baseline) | Anti-O:2 IgG antibodies in serum were measured by an ELISA assay. Blood samples were collected at specified timepoints. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint. |
| Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | At Day 1, Day 29, Day 169, Day 176 and Day 197 | Blood samples were collected at specified timepoint for each component as measured by ELISA. |
| Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | At Day 1, Day 29, Day 169, Day 176 and Day 197 | Blood samples were collected at specified timepoint for each component as measured by ELISA. |
| Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | At Day 29, Day 169, Day 176 and Day 197 compared to Day 1 (baseline) | Blood samples were collected at specified timepoint for each component as measured by ELISA. 4-fold increase was defined as 4 times the baseline value of anti-O:2 IgG antibody concentrations. |
| Number of Participants With Any SAE | From Day 197 to Day 337 | An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. |
Countries
Belgium
Participant flow
Pre-assignment details
Out of 97 participants enrolled, 1 participant, who underwent post-screening procedures, withdrew from the study before randomisation and did not receive the study intervention. Therefore, 96 participants were randomised in the study.
Participants by arm
| Arm | Count |
|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum Participants received a low dose of the TYP04A vaccine without Alum intramuscularly on Day 1 and Day 169. | 12 |
| Step 1b: Low Dose TYP03A Vaccine With Alum Participants received low dose of the TYP03A vaccine with Alum intramuscularly on Day 1 and Day 169. | 12 |
| Step 2: Full Dose TYP04B Vaccine Without Alum Participants received full dose of the TYP04B vaccine without Alum intramuscularly on Day 1 and day 169. | 24 |
| Step 2: Full Dose TYP03B Vaccine With Alum Participants received full dose of the TYP03B vaccine with Alum intramuscularly on Day 1 and day 169. | 24 |
| Control: TYPHIM VI and BOOSTRIX Vaccine Participants received TYPHIM VI as the comparator intramuscularly on Day 1 and BOOSTRIX as the comparator on Day 169. | 24 |
| Total | 96 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 0 | 1 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 1 | 0 |
Baseline characteristics
| Characteristic | Step 1a: Low Dose TYP04A Vaccine Without Alum | Step 1b: Low Dose TYP03A Vaccine With Alum | Step 2: Full Dose TYP04B Vaccine Without Alum | Step 2: Full Dose TYP03B Vaccine With Alum | Control: TYPHIM VI and BOOSTRIX Vaccine | Total |
|---|---|---|---|---|---|---|
| Age, Continuous | 31.9 Years STANDARD_DEVIATION 10.8 | 31.8 Years STANDARD_DEVIATION 8.4 | 27.0 Years STANDARD_DEVIATION 9.2 | 27.1 Years STANDARD_DEVIATION 9.8 | 30.7 Years STANDARD_DEVIATION 10.6 | 29.2 Years STANDARD_DEVIATION 9.9 |
| Race/Ethnicity, Customized White | 12 Participants | 12 Participants | 24 Participants | 24 Participants | 24 Participants | 96 Participants |
| Sex/Gender, Customized Female | 11 Participants | 6 Participants | 14 Participants | 17 Participants | 18 Participants | 66 Participants |
| Sex/Gender, Customized Male | 1 Participants | 6 Participants | 10 Participants | 7 Participants | 6 Participants | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 12 | 0 / 24 | 0 / 24 | 0 / 24 |
| other Total, other adverse events | 9 / 12 | 12 / 12 | 24 / 24 | 24 / 24 | 24 / 24 |
| serious Total, serious adverse events | 0 / 12 | 0 / 12 | 0 / 24 | 0 / 24 | 0 / 24 |
Outcome results
Primary
Number of Participants With AEs Leading to Withholding Further Study Intervention Administration
An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. AEs that lead to withholding of the study intervention administration were considered under this outcome measure.
Time frame: From Day 1 to Day 197
Population: The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With AEs Leading to Withholding Further Study Intervention Administration | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With AEs Leading to Withholding Further Study Intervention Administration | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With AEs Leading to Withholding Further Study Intervention Administration | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With AEs Leading to Withholding Further Study Intervention Administration | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With AEs Leading to Withholding Further Study Intervention Administration | 1 Participants |
Primary
Number of Participants With AEs/SAEs Leading to Withdrawal From the Study
Any AEs including SAEs that lead to withdrawal from the study are considered under this outcome measure. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.
Time frame: From Day 1 to Day 197
Population: The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
Primary
Number of Participants With Any Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: From Day 1 to Day 197
Population: The analysis was performed on the exposed set, which included all participants who received at least 1 dose of the study intervention. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Any Serious Adverse Events (SAEs) | 0 Participants |
Primary
Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, hematocrit, lymphocytes, monocytes, neutrophils, platelets, leukocytes. Hepatic laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and renal laboratory parameters include creatinine and blood urea. Categories reported when comparing Day 169 (baseline) and Day 176 hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Range level being classified as below, within or above the normal range.
Time frame: At Day 176 compared to Day 169 (Baseline)
Population: The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in the analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Below | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Within | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Within | 7 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Within | 6 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Within | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Within | 7 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Within | 7 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Within | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Within | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Above | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Below | 2 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Within | 7 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Above | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Within | 18 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Within | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Within | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Within | 19 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Above | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Within | 18 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Within | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Within | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Within | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Within | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Within | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Within | 18 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Within | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Above | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Within | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Within | 18 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Within | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Within | 19 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Within | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Within | 20 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Within | 20 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Within | 19 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Below | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Above | 2 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Within | 21 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Within | 20 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Within | 21 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Within | 20 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Within | 19 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Within | 20 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Within | 21 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Within | 21 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Within | 19 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Above | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Basophils-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Lymphocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Within | 20 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Within | 19 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Within | 20 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Within | 21 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hematocrit-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Within-Below | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Blood urea-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Within | 21 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Monocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Above | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Above | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | AST-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Leukocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Platelets-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Within | 20 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Within-Within | 18 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | ALT-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Within-Within | 15 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Hemoglobin-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Erythrocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Neutrophils-Above-Within | 6 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Eosinophils-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176 | Creatinine-Above-Below | 0 Participants |
Primary
Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8
Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, hematocrit, lymphocytes, monocytes, neutrophils, platelets, leukocytes. Hepatic laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and renal laboratory parameters include creatinine and blood urea. Categories reported when comparing Day 1 (baseline) and Day 8 hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Range level being classified as below, within or above the normal range.
Time frame: At Day 8 compared to Day 1 (Baseline)
Population: The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in the analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Within | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Above | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Above | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Within | 11 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Within | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Within | 11 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Within | 11 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Above | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Within | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Within | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Within | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Above | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Within | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Within | 10 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Within | 10 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Below | 2 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Within | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Within | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below -Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Within | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Within | 9 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Below | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Within | 11 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Within | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Above | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Above | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Below | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Within | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Above | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Within | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Within | 12 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Within | 11 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Above | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Below | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Within | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Within | 11 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Above | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Within | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Below | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Above | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Below | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Within | 11 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Within | 12 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Above | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Within | 12 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Within | 12 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below -Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Within | 11 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Within | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Within | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Above | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Below | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Within | 22 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Above | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Within | 23 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Within | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Within | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Within | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Above | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Within | 22 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Within | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Below | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Below | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Below | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Within | 23 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below -Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Within | 23 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Within | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Within | 23 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Above | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Within | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Within | 23 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Within | 21 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Above | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Below | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Within | 3 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Within | 20 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Within | 24 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Within | 24 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Within | 23 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below -Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Within | 23 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Within | 2 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Within | 2 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Within | 24 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Within | 23 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Within | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Below | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Within | 21 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Above | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Below | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Within | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Within | 23 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Within | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Above | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Within | 24 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Above | 3 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Within | 23 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Within | 20 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Creatinine-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Within | 22 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Within | 23 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | AST-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Within | 24 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | ALT-Below -Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Within | 22 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Within | 2 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Within | 24 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hemoglobin-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Within | 23 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Hematocrit-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Erythrocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Within-Within | 24 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Within | 24 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Blood urea-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Eosinophils-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Within | 24 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Within | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Within | 23 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Above-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Within-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Monocytes-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Basophils-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Neutrophils-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Within-Above | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Platelets-Below-Below | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Above-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Within-Within | 24 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Lymphocytes-Below-Within | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8 | Leukocytes-Below-Within | 2 Participants |
Primary
Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. SAEs that lead to withholding of the study intervention administration were considered under this outcome measure.
Time frame: From Day 1 to Day 197
Population: The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration | 0 Participants |
Primary
Number of Participants With Solicited Administration-site Events After the First Vaccination
Solicited administration site events included pain, redness, and swelling.
Time frame: From Day 1 to Day 7
Population: The analysis was performed on the solicited safety set, which included all participants who received at least 1 dose of the study intervention and had solicited safety data during the specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Pain | 3 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Swelling | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Redness | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Redness | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Pain | 11 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Swelling | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Redness | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Pain | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Swelling | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Pain | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Swelling | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the First Vaccination | Redness | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Administration-site Events After the First Vaccination | Redness | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Administration-site Events After the First Vaccination | Pain | 17 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Administration-site Events After the First Vaccination | Swelling | 1 Participants |
Primary
Number of Participants With Solicited Administration-site Events After the Second Vaccination
Solicited administration site events included pain, redness, and swelling.
Time frame: From Day 169 to Day 175
Population: The analysis was performed on the Solicited safety set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Pain | 6 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Swelling | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Redness | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Redness | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Pain | 6 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Swelling | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Redness | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Pain | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Swelling | 2 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Pain | 19 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Swelling | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Redness | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Redness | 1 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Pain | 13 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Administration-site Events After the Second Vaccination | Swelling | 0 Participants |
Primary
Number of Participants With Solicited Systemic Events After the First Vaccination
The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), fever, headache, and myalgia (muscle pain). Fever is defined as body temperature more than or equal to (\>=) 38.0 degrees Celsius (°C).
Time frame: From Day 1 to Day 7
Population: The analysis was performed on the Solicited safety set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Headache | 5 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Arthralgia | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Myalgia | 3 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fatigue | 4 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fever | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Headache | 5 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fever | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fatigue | 3 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Myalgia | 3 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Arthralgia | 3 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fever | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Arthralgia | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fatigue | 9 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Headache | 10 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Myalgia | 7 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Myalgia | 15 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Arthralgia | 2 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Headache | 6 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fever | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the First Vaccination | Fatigue | 12 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the First Vaccination | Fever | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the First Vaccination | Headache | 11 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the First Vaccination | Arthralgia | 2 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the First Vaccination | Myalgia | 9 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the First Vaccination | Fatigue | 11 Participants |
Primary
Number of Participants With Solicited Systemic Events After the Second Vaccination
The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), fever, headache, and myalgia (muscle pain).
Time frame: From Day 169 to Day 175
Population: The analysis was performed on the Solicited safety set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Headache | 2 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Arthralgia | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Myalgia | 3 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fatigue | 1 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fever | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Headache | 3 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fever | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fatigue | 3 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Myalgia | 3 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Arthralgia | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fever | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Arthralgia | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fatigue | 6 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Headache | 9 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Myalgia | 9 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Myalgia | 9 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Arthralgia | 2 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Headache | 9 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fever | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fatigue | 9 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fever | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the Second Vaccination | Headache | 9 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the Second Vaccination | Arthralgia | 3 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the Second Vaccination | Myalgia | 9 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Solicited Systemic Events After the Second Vaccination | Fatigue | 9 Participants |
Primary
Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination
An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.
Time frame: From Day 1 to Day 28
Population: The analysis was performed on the unsolicited safety set, which included all participants who received at least 1 dose of the study intervention and reported having/not having unsolicited AEs during the specified timepoints.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination | 7 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination | 9 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination | 15 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination | 12 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination | 14 Participants |
Primary
Number of Participants With Unsolicited Adverse Events After the Second Vaccination
An unsolicited adverse event is defined as an adverse event that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.
Time frame: From Day 169 to Day 196
Population: The analysis was performed on the unsolicited safety set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Unsolicited Adverse Events After the Second Vaccination | 1 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Unsolicited Adverse Events After the Second Vaccination | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Unsolicited Adverse Events After the Second Vaccination | 11 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Unsolicited Adverse Events After the Second Vaccination | 8 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Unsolicited Adverse Events After the Second Vaccination | 4 Participants |
Secondary
Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations
Anti-Vi specific IgG antibodies were measured by an anti-Vi IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit. Blood samples were collected at specified timepoints.
Time frame: At Day 1 (pre-dose 1), Day 29, Day 169 (pre-Dose 2), Day 176 and Day 197
Population: The analysis was performed on Per-protocol set, which included all eligible participants who received each dose as per-protocol, had immunogenicity results post- dose, complied with dosing/blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination during the specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 176 | 10.90 microgram per milliliter (µg/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 1 (pre-dose 1) | 1.10 microgram per milliliter (µg/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 197 | 10.16 microgram per milliliter (µg/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 29 | 14.12 microgram per milliliter (µg/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 169 (pre-Dose 2) | 4.36 microgram per milliliter (µg/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 176 | 18.78 microgram per milliliter (µg/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 169 (pre-Dose 2) | 11.17 microgram per milliliter (µg/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 29 | 19.61 microgram per milliliter (µg/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 197 | 18.88 microgram per milliliter (µg/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 1 (pre-dose 1) | 1.52 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 169 (pre-Dose 2) | 18.58 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 1 (pre-dose 1) | 1.14 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 29 | 60.52 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 176 | 32.38 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 197 | 33.75 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 197 | 37.14 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 1 (pre-dose 1) | 1.17 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 176 | 56.78 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 169 (pre-Dose 2) | 12.55 microgram per milliliter (µg/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 29 | 36.97 microgram per milliliter (µg/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 169 (pre-Dose 2) | 6.18 microgram per milliliter (µg/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 176 | 5.15 microgram per milliliter (µg/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 1 (pre-dose 1) | 1.10 microgram per milliliter (µg/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 197 | 5.17 microgram per milliliter (µg/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations | Day 29 | 4.95 microgram per milliliter (µg/mL) |
Secondary
Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations
Anti-Vi specific IgG antibodies were measured by an anti-Vi IgG ELISA kit. Blood samples were collected at specified timepoints. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint.
Time frame: At Day 29, Day 169, Day 176, and Day 197 compared to Day 1 (baseline)
Population: The analysis was performed on the Per-protocol set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 29 | 12.84 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 169 | 3.96 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 9.91 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 9.23 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 29 | 12.90 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 11.00 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 169 | 7.11 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 11.96 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 29.22 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 169 | 16.27 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 28.19 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 29 | 53.01 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 29 | 31.55 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 169 | 10.65 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 31.04 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 47.45 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 4.70 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 4.68 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 169 | 5.62 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Geometric Mean Ratio (GMR) for Anti-Vi Antigen IgG Antibody Concentrations | Day 29 | 4.50 Ratio |
Secondary
GMC of Anti-O:2 IgG Antibody Concentrations
Anti-O:2 IgG antibodies in serum were measured by an ELISA assay. Blood samples were collected at specified timepoints.
Time frame: At Day 1 (pre-dose 1), Day 29, Day 169 (pre-dose 2), Day 176 and Day 197
Population: The analysis was performed on the Per-protocol set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 169 (pre-dose 2) | 702.49 ELISA Units per milliliter (EU/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 29 | 4150.79 ELISA Units per milliliter (EU/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 1 (pre-dose 1) | 36.35 ELISA Units per milliliter (EU/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 197 | 958.21 ELISA Units per milliliter (EU/mL) |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 176 | 1079.75 ELISA Units per milliliter (EU/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 176 | 464.70 ELISA Units per milliliter (EU/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 1 (pre-dose 1) | 28.31 ELISA Units per milliliter (EU/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 29 | 559.62 ELISA Units per milliliter (EU/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 169 (pre-dose 2) | 298.02 ELISA Units per milliliter (EU/mL) |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 197 | 520.77 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 197 | 956.89 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 169 (pre-dose 2) | 894.08 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 176 | 1342.38 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 29 | 4110.58 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 1 (pre-dose 1) | 25.28 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 29 | 668.30 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 197 | 388.50 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 169 (pre-dose 2) | 268.09 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 1 (pre-dose 1) | 25.90 ELISA Units per milliliter (EU/mL) |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMC of Anti-O:2 IgG Antibody Concentrations | Day 176 | 522.60 ELISA Units per milliliter (EU/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMC of Anti-O:2 IgG Antibody Concentrations | Day 176 | 18.24 ELISA Units per milliliter (EU/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMC of Anti-O:2 IgG Antibody Concentrations | Day 197 | 17.28 ELISA Units per milliliter (EU/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMC of Anti-O:2 IgG Antibody Concentrations | Day 169 (pre-dose 2) | 18.43 ELISA Units per milliliter (EU/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMC of Anti-O:2 IgG Antibody Concentrations | Day 1 (pre-dose 1) | 22.15 ELISA Units per milliliter (EU/mL) |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMC of Anti-O:2 IgG Antibody Concentrations | Day 29 | 28.19 ELISA Units per milliliter (EU/mL) |
Secondary
GMR for Anti-O:2 IgG Antibody Concentrations
Anti-O:2 IgG antibodies in serum were measured by an ELISA assay. Blood samples were collected at specified timepoint. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint.
Time frame: At Day 176 and Day 197 compared to Day 169 (baseline)
Population: The analysis was performed on the Per-protocol set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 1.54 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 1.36 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 1.56 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 1.70 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 1.76 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 1.60 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 2.01 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 1.89 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 0.98 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 0.99 Ratio |
Secondary
GMR for Anti-O:2 IgG Antibody Concentrations
Anti-O:2 IgG antibodies in serum were measured by an ELISA assay. Blood samples were collected at specified timepoints. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint.
Time frame: At Day 29, Day 169, Day 176, and Day 197 compared to Day 1 (baseline)
Population: The analysis was performed on the Per-protocol set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 35.66 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 169 | 26.15 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 40.19 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 29 | 114.19 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 19.23 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 29 | 19.77 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 169 | 9.11 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 14.20 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 169 | 37.28 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 51.16 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 68.01 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 29 | 162.61 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 19.12 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 169 | 9.15 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 29 | 25.81 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 17.86 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-O:2 IgG Antibody Concentrations | Day 197 | 0.95 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-O:2 IgG Antibody Concentrations | Day 29 | 1.27 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-O:2 IgG Antibody Concentrations | Day 176 | 0.86 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-O:2 IgG Antibody Concentrations | Day 169 | 0.92 Ratio |
Secondary
GMR for Anti-Vi Antigen IgG Antibody Concentrations
Anti-Vi specific IgG antibodies were measured by an anti-Vi IgG ELISA kit. Blood samples were collected at specified timepoints. Within participant GMRs were calculated as ratio of concentration in the post-vaccination timepoint to the pre-vaccination timepoint.
Time frame: At Day 176 and Day 197 compared to Day 169 (baseline)
Population: The analysis was performed on the Per-protocol set. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 2.50 Ratio |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 2.33 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 1.68 Ratio |
| Step 1b: Low Dose TYP03A Vaccine With Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 1.72 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 2.00 Ratio |
| Step 2: Full Dose TYP04B Vaccine Without Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 1.71 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 3.08 Ratio |
| Step 2: Full Dose TYP03B Vaccine With Alum | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 4.20 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 176 | 0.82 Ratio |
| Control: TYPHIM VI and BOOSTRIX Vaccine | GMR for Anti-Vi Antigen IgG Antibody Concentrations | Day 197 | 0.77 Ratio |
Secondary
Number of Participants With AEs/SAEs Leading to Withdrawal From the Study
Any AEs including SAEs that lead to withdrawal from the study are considered under this outcome measure. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.
Time frame: From Day 197 to Day 337
Population: The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With AEs/SAEs Leading to Withdrawal From the Study | 0 Participants |
Secondary
Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL
Blood samples were collected at specified timepoint for each component as measured by ELISA.
Time frame: At Day 1, Day 29, Day 169, Day 176 and Day 197
Population: The analysis was performed on FAS. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 176 | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 1 | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 197 | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 29 | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 169 | 6 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 176 | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 169 | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 29 | 11 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 197 | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 1 | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 169 | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 1 | 1 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 29 | 22 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 176 | 19 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 197 | 21 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 197 | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 1 | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 176 | 21 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 169 | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 29 | 23 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 169 | 17 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 176 | 16 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 1 | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 197 | 16 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations >= 2.0 µg/mL | Day 29 | 20 Participants |
Secondary
Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL)
Blood samples were collected at specified timepoint for each component as measured by ELISA.
Time frame: At Day 1, Day 29, Day 169, Day 176 and Day 197
Population: The analysis was performed on Full Analysis Set (FAS), which included all participants who received at least 1 dose of the study intervention and had post- vaccination immunogenicity data during the specified timepoints.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 176 | 6 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 1 | 0 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 197 | 7 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 29 | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 169 | 6 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 176 | 9 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 169 | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 29 | 10 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 197 | 9 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 1 | 2 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 169 | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 1 | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 29 | 22 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 176 | 19 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 197 | 20 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 197 | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 1 | 1 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 176 | 21 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 169 | 18 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 29 | 23 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 169 | 13 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 176 | 12 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 1 | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 197 | 12 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Anti-Vi Antigen IgG Antibody Concentrations Greater Than or Equal to (>=) 4.3 Micrograms Per Milliliter (µg/mL) | Day 29 | 13 Participants |
Secondary
Number of Participants With Any SAE
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: From Day 197 to Day 337
Population: The analysis was performed on the exposed set. Only participants with data available at the mentioned timepoints were included in the analysis.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With Any SAE | 0 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With Any SAE | 0 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With Any SAE | 0 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With Any SAE | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With Any SAE | 0 Participants |
Secondary
Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations
Blood samples were collected at specified timepoint for each component as measured by ELISA. 4-fold increase was defined as 4 times the baseline value of anti-O:2 IgG antibody concentrations.
Time frame: At Day 29, Day 169, Day 176 and Day 197 compared to Day 1 (baseline)
Population: The analysis was performed on FAS. Only participants with data available at the mentioned timepoints were included in this analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 29 | 12 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 169 | 7 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 176 | 8 Participants |
| Step 1a: Low Dose TYP04A Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 197 | 8 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 29 | 9 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 197 | 9 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 169 | 7 Participants |
| Step 1b: Low Dose TYP03A Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 176 | 8 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 197 | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 169 | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 176 | 20 Participants |
| Step 2: Full Dose TYP04B Vaccine Without Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 29 | 22 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 29 | 20 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 169 | 16 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 197 | 19 Participants |
| Step 2: Full Dose TYP03B Vaccine With Alum | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 176 | 18 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 197 | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 176 | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 169 | 0 Participants |
| Control: TYPHIM VI and BOOSTRIX Vaccine | Number of Participants With at Least 4-fold Increase in Anti-O:2 IgG Antibody Concentrations | Day 29 | 1 Participants |